This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Plethora may get $28mm through arrangement with Paul Capital
17 Sep 2014
Plethora Solutions Holdings PLC (urological conditions) has signed an agreement with Paul Capital Healthcare under which Plethora gets up to $28mm--$15mm cash up front, $10mm cash upon the first US sale of PSD502, and $3mm in equity--in exchange for revenue interest in Plethora's male health portfolio. The interest will mainly come from ErecAid (sold by the company's Timm Medical subsidiary for erectile dysfunction), PSD502 (Phase III for premature ejaculation and erectile dysfunction), and PSD510 (Phase III for erectile dysfunction).
Diagnostic Equipment & Supplies
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?